Timothy J. Perlman

Chief Technology Officer

Tim is a member of HDL Therapeutics, Inc. leadership team, and has worked in the biomedical industry for over 20 years. He has a strong background in blood and plasma based new product/process development from concept through launch, and has led high performing teams, partners, and clinical sites to execute the development and implementation of cutting edge medical technologies. He is well versed in the U.S. and International regulatory requirements for medical devices.

Tim led the design and development of HDL Therapeutics’ Plasma Delipidation System, and oversaw the successful completion of the first-in-man clinical feasibility study. Over the course of his career, he has also been responsible for the development of a number of other blood/plasma processing therapies, including novel lipoprotein modification processes and systems, extracorporeal xenogeneic liver assist systems, and innovative pathogen inactivation processes intended to treat SIV and HIV. Tim has led programs in the diabetes management field, from the design and development of innovative xenogeneic implantable artificial pancreas devices, to next generation integrated blood glucose monitoring systems. Tim has published numerous abstracts and articles in such Journals as the Journal of the American College of Cardiology and the Journal of Lipid Research, and holds over a dozen issued patents in the field.

Tim received his Bachelor of Science in Mechanical Engineering with High Honors from Northeastern University in Boston, and conducted graduate studies in Biomedical Engineering at Worcester Polytechnic Institute in Worcester, Massachusetts.